Watchman Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-3,820
Closed -$428K 87
2021
Q4
$428K Sell
3,820
-1,140
-23% -$137K 0.22% 61
2021
Q3
$624K Sell
4,960
-730
-13% -$94K 0.4% 52
2021
Q2
$770K Sell
5,690
-450
-7% -$59.2K 0.45% 57
2021
Q1
$833K Sell
6,140
-1,860
-23% -$278K 0.51% 54
2020
Q4
$1.13M Sell
8,000
-210
-3% -$26.9K 0.75% 52
2020
Q3
$914K Sell
8,210
-850
-9% -$95.3K 0.68% 53
2020
Q2
$1.01M Hold
9,060
0.84% 50
2020
Q1
$702K Sell
9,060
-660
-7% -$58.4K 0.72% 48
2019
Q4
$924K Buy
+9,720
New +$841K 0.69% 50

Other funds holding XBI

Watchman Group's XBI Position: Q1 2022 in Review

Watchman Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 3,820 shares — an estimated $428K sold.

Watchman Group first reported a position in XBI in Q4 2019 and held it in 9 quarters. The position peaked at $1.13M in Q4 2020. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Watchman Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Watchman Group sold 3,820 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $428K.
  • Watchman Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and held it in 9 quarters.
  • Watchman Group's State Street SPDR S&P Biotech ETF position peaked at $1.13M in Q4 2020.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Watchman Group's 13F filing for Q1 2022, filed 16 May 2022.